Compare ENTX & MGYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ENTX | MGYR |
|---|---|---|
| Founded | 2010 | 1922 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Savings Institutions |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 147.4M | 123.2M |
| IPO Year | 2015 | 2021 |
| Metric | ENTX | MGYR |
|---|---|---|
| Price | $3.11 | $23.00 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $9.75 | N/A |
| AVG Volume (30 Days) | ★ 569.4K | 5.9K |
| Earning Date | 11-17-2026 | 10-28-2026 |
| Dividend Yield | N/A | ★ 2.10% |
| EPS Growth | N/A | ★ 26.83 |
| EPS | 0.22 | ★ 1.47 |
| Revenue | ★ $42,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $13.95 | $15.84 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.91 | $16.03 |
| 52 Week High | $4.20 | $23.99 |
| Indicator | ENTX | MGYR |
|---|---|---|
| Relative Strength Index (RSI) | 56.02 | 79.58 |
| Support Level | $2.64 | $17.00 |
| Resistance Level | $3.26 | N/A |
| Average True Range (ATR) | 0.24 | 0.64 |
| MACD | 0.03 | 0.36 |
| Stochastic Oscillator | 70.00 | 76.31 |
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
Magyar Bancorp Inc is an independent, community financial services provider offering traditional banking services to individual, business, and government customers. The Company attracts retail deposits through its main office in New Brunswick, New Jersey, and branch offices in Middlesex and Somerset Counties, and invests those funds mainly in commercial and residential real estate loans, commercial business loans, SBA loans, home equity loans and lines of credit, construction and land loans, and investment securities. Revenues are derived mainly from interest on loans and securities and from fees and service charges, with lending relationships focused on small to mid-sized businesses and individual consumers in central and northern New Jersey.